Live news related to IPSEN stock (FR0010259150): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Ipsen closes a contrasting week on a negative note, while the CAC 40 advances over 1% during the session. The decline of the biopharmaceutical laborat…
The biopharmaceutical laboratory has closed the acquisition of American company Kartos Therapeutics, adding navtemadlin to its portfolio, an experimen…
The biopharmaceutical laboratory stock rebounded during Tuesday's session, advancing among the strongest gains on the SBF 120 index in an almost stabl…
On July 22, 2026, Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a Swiss biotechnology company. This acquisition grants th…
In mid-morning trading in Paris, the biopharmaceutical company continues its decline in a downward-trending Parisian market. The stock is erasing some…
The biopharmaceutical laboratory experiences a sharp decline in the morning, following a major clinical announcement about its botulinum toxin. The st…
On July 9, 2026, Ipsen announced positive Phase III results for Dysport in the prevention of both episodic and chronic migraine, becoming the first la…
The biopharmaceutical company stands out in the late Paris session, continuing an upward trend that started several weeks ago. The stock is testing a …
French pharmaceutical company Ipsen announced on Wednesday the acquisition of Swiss biotech firm Memo Therapeutics AG to bolster its rare disease port…
In early afternoon trading, the French biopharmaceutical company stands out in a sluggish Paris market. The stock continues its upward trend from rece…
